Answers are grounded in this paper and cite their sources.
Resistance to the action of insulin in its metabolic target tissues occurs in almost all patients with type 2 diabetes and forms the pathophysiologic basis of the visceral obesitylinked metabolic syndrome. Improving tissue sensitivity to insulin is a major clinical goal to help ameliorate not only abnormal glucose metabolism, but also some of the cardiovascular risk factors that accompany this syndrome. Proteintyrosine phosphatases (PTPases) that function as negative regulators of the insulin signaling cascade have been identified as novel targets for the therapeutic enhancement of insulin action in insulin-resistant disease states. Recent studies have provided compelling evidence that one of the main functions of the intracellular enzyme PTPase 1B (PTP1B), and perhaps to a lesser extent the transmembrane PTPase leukocyte antigen-related (LAR), is to suppress insulin action. Reducing PTP1B abundance not only enhances insulin sensitivity and improves glucose metabolism but also protects against obesity induced by high-fat feeding. Inhibition of PTP1B in insulin target tissues using pharmaceutical agents and novel antisense oligonucoleotides has shown enhanced insulin signaling and glucose tolerance in preclinical models. PTPase inhibitors may eventually find an important clinical role as novel insulin sensitizers in the management of type 2 diabetes and the metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Barry J. Goldstein (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: